Pharmaceutical company Upsher-Smith Laboratories LLC reported on Friday the availability of Diphenoxylate Hydrochloride and Atropine Sulfate Tablets in USP, 2.5 mg/0.025 mg in the US.
The company said the Diphenoxylate Hydrochloride and Atropine Sulfate Tablets in USP, 2.5 mg/0.025 mg is an AA-rated generic version of the branded product, Lomotil (diphenoxylate hydrochloride and atropine sulfate tablets). Lomotil is a registered trademark of GD Searle LLC and the combination prescription drug is used to treat the symptoms of acute or chronic diarrhea.
For the 12 months ending May 2018, the diphenoxylate hydrochloride and atropine sulfate tablet market had US sales of approximately USD64m, according to IQVIA.
In conjunction, Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP are classified as a Schedule V controlled substance.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling